Abstract
The objective of the study is to investigate the functional ability, i.e., the physical aspect of the health-related quality of life and its determining factors during therapy with etanercept in children with juvenile idiopathic arthritis (JIA). Assessment of the Child Health Assessment Questionnaire (CHAQ), the number of active joints, duration of morning stiffness, ESR, C-reactive protein, parent’s global assessment of the overall patient’s well-being, physician’s global assessment of the overall disease activity, concomitant treatment with methotrexat, number of aids/devices needed, and calculation of the PedACR-score. Data of 437 children were analyzed for disease severity and impact of the disease on functional abilities. Data of 114 children with a complete data set and a continuous treatment for at least 24 months were used for analysis of the impact of treatment on functional abilities. Before treatment with etanercept, patients with systemic arthritis and seropositive or seronegative polyarthritis were disabled more heavily than those with other subtypes of JIA. There was a correlation between high CHAQ scores and the number of active joints, aids/devices needed, parent’s global assessment of the overall patient’s well-being, morning stiffness, physician’s global assessment of the overall disease activity, and C-reactive protein (P < 0.005). Of the eight areas, “dressing and grooming”, “arising”, “eating”, “walking”, “hygiene”, “reach”, “grip” and “activities”, the latter was most severely affected. 96.5, 93.8, and 90.3% of the patients reached a PedACR-30, -50 and -70 score upon treatment with etanercept for 24 months. The areas of eating and walking were best before therapy and showed highest improvement with therapy. Under therapy with etanercept patients of all JIA subgroups significantly improved their functional ability (P < 0.0001), but patients with polyarthritis less frequently improved their physical functioning. Disease activity and the physical aspect of health-related quality of life including functional ability improved significantly during therapy with etanercept in children with JIA. Duties of everyday life were easier to accomplish.
Similar content being viewed by others
References
Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25:1991–1994
Woo P, Wedderburn LR (1998) Juvenile chronic arthritis. Lancet 351:969–973
Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton J, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore JB, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–769. doi:10.1056/NEJM200003163421103
Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore JB, White B, Giannini EH (2006) Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 54:1987–1994. doi:10.1002/art.21885
Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Carol A, Chon Y, Lin SL, Baumgartner SW, Giannini EH, Nickeson RW Jr, Jones OY, Schneider R, Nocton J, Stein LD, Gedalia A, Whitmore JB, White B, Bernstein B, Cawkwell GD, Feldman B, Gottlieb B, Graham B, Laxer R, Olson JC, Passo M, Reed A, Shaham B, Sher M, Sherry D, Silverman ED (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496–1504. doi:10.1002/art.23427
Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Küster RM, Michels H, Moebius D, Rogalski B, Thon A (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638–1644. doi:10.1136/ard.2003.014886
Kietz DA, Pepmueller PH, Moore TL (2001) Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J Rheumatol 28:360–362
Kietz DA, Pepmueller PH, Moore TL (2002) Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 61:171–173. doi:10.1136/ard.61.2.171
Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry. Ann Rheum Dis 68(4):519–525
Lahdenne P, Vähäsalo P, Honkanen V (2003) Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62:245–247. doi:10.1136/ard.62.3.245
Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM (2003) Efficacy of Etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48:1093–1101. doi:10.1002/art.10885
Robinson RF, Nahata MC, Hayes JR, Rennebohm R, Higgins G (2007) Quality-of-life measurements in juvenile rheumatoid arthritis patients treated with etanercept. Clin Drug Investig 23:511–518. doi:10.2165/00044011-200323080-00003
Prince FH, Twilt M, Ten Cate R, Van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW (2009) Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 68(5):635–641
Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, Tortorelli A, Landgraf JM, Singh G, Martini A (2001) Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 19:1–9
Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40:1202–1209
Ruperto N, Ravelli A, Falcini F, Lepore L, Buoncompagni A, Gerloni V et al (1999) Responsiveness of outcome measures in juvenile chronic arthritis. Rheumatology 38:176–180. doi:10.1093/rheumatology/38.2.176
Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SKF, Falcini F et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50:2191–2201. doi:10.1002/art.20288
Van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, Ten Cate R, Suijlekom-Smit LW et al (1998) Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 41:808–816. doi:10.1002/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T
Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R et al (2005) A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum 52:563–572. doi:10.1002/art.20860
Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096–3106. doi:10.1002/art.22838
Foeldvari I, Ruperto N, Dressler F, Hafner R, Kuster RM, Michels H, Minden K, Schauer-Petrowskaja C, Bullinger M, Landgraf JM, Huppertz HI (2001) The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 19:71–75
Duffy CM (2005) Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: clinical science for the pediatrician. Pediatr Clin North Am 52:359–372. doi:10.1016/j.pcl.2005.01.009
Oliveira S, Ravelli A, Pistorio A, Castell E, Malattia C, Prieur AM, Saad-Magalhaes C, Murray KJ, Bae SC, Joos R, Foeldvari I, Duarte-Salazar C, Wulffraat N, Lahdenne P, Dolezalova P, De Inocencio J, Kanakoudi-Tsakalidou F, Hofer M, Nikishina I, Ozdogan H, Hashkes PJ, Landgraf JM, Martini A, Ruperto N (2007) Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum 57:35–43. doi:10.1002/art.22473
Bekkering WP, Ten CR, Van Rossum MA, Vliet Vlieland TP (2007) A comparison of the measurement properties of the Juvenile Arthritis Functional Assessment Scale with the childhood health assessment questionnaire in daily practice. Clin Rheumatol 26:1903–1907. doi:10.1007/s10067-007-0689-8
Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID (2003) Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 48:767–775. doi:10.1002/art.10863
Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schontube M, Zink A (2002) Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 46:2392–2401. doi:10.1002/art.10444
Horneff G, Forster J, Seyberth HW, Michels H (2001) Arbeitgemeinschaft Kinder- und Jugendrheumatologie. Recommendations by the Pediatric and Adolescent Rheumatology Study Committee on therapy with Etanercept (p75 TNF-alpha receptor immunoglobulin fusion protein). Pharmacotherapy Committee. Z Rheumatol 59:365–369. doi:10.1007/s003930070043
Ruperto N, Levinson JE, Ravelli A, Shear ES, Link Tague B, Murray K, Martini A, Giannini EH (1997) Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol 24:945–951
Schmeling H, Mathony K, John V, Keyßer G, Burdach S, Horneff G (2001) A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis 60:410–412. doi:10.1136/ard.60.4.410
Pouchot J, Ecosse E, Coste J, Guillemin F (2004) Validity of the childhood health assessment questionnaire is independent of age in juvenile idiopathic arthritis. Arthritis Rheum 51:519–526. doi:10.1002/art.20529
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Halbig, M., Horneff, G. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int 30, 229–238 (2009). https://doi.org/10.1007/s00296-009-0942-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-0942-3